Determination of Clonal Origin of Recurrent Hepatocellular Carcinoma for Personalized Therapy and Outcomes Evaluation: A New Strategy for Hepatic Surgery

Abstract

The MO-type RHCC was closely associated with better postoperative outcomes when compared with the IM-type RHCC. Generally, we recommend liver re-resection for MO-type RHCC, and interventional therapy for IM-type RHCC. Microdissection-based microsatellite loss of heterozygosity protocol has advantages in assessing the clonal origin, modes of personalized treatment, and clinical outcomes of RHCC.